PPIs Flashcards
What are the typical doses of omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole?
A:
Omeprazole: 20-40 mg once or twice daily
Lansoprazole: 15-30 mg once daily
Pantoprazole: 20-40 mg once or twice daily
Rabeprazole: 20 mg once daily
Esomeprazole: 20-40 mg once daily
Dexlansoprazole: 30-60 mg once daily
In what situations might one PPI be preferred over another?
A:
Lansoprazole and dexlansoprazole may be preferred in patients who need once-daily dosing or who have difficulty swallowing capsules.
Pantoprazole and rabeprazole may be preferred in patients with liver disease or impaired liver function.
Esomeprazole may be preferred in patients with persistent symptoms despite treatment with other PPIs.
What types of drugs may require the use of PPIs for stomach protection?
A:
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Bisphosphonates
Steroids
Which PPI has the longest half-life?
A: Dexlansoprazole has the longest half-life of all the PPIs.
Can PPIs be taken with other medications?
A: Yes, PPIs can be taken with many other medications, but they may interact with certain drugs.
What is rebound acid hypersecretion and how can it be avoided?
A: Rebound acid hypersecretion is a possible side effect of stopping PPIs abruptly after long-term use. It can be avoided by tapering off PPIs gradually.
What is the recommended duration of PPI treatment?
A: PPIs should be used at the lowest effective dose and for the shortest duration necessary to control symptoms.
Can PPIs be used in children?
A: PPIs can be used in children, but the dose and duration of treatment may be different compared to adults.
What is the association between PPIs and chronic kidney disease?
A: Long-term use of PPIs has been associated with an increased risk of chronic kidney disease, especially in patients who take them long-term.
What is the preferred PPI for patients with liver disease?
A: Pantoprazole and rabeprazole may be preferred in patients with liver disease or impaired liver function, as they have fewer interactions with liver enzymes compared to other PPIs.
